Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Target Raised at Royal Bank Of Canada

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target increased by investment analysts at Royal Bank Of Canada from $576.00 to $600.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the pharmaceutical company’s stock. Royal Bank Of Canada‘s price objective would indicate a potential upside of 10.80% from the company’s previous close.

VRTX has been the topic of several other research reports. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Barclays boosted their price target on shares of Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Jefferies Financial Group increased their price objective on shares of Vertex Pharmaceuticals from $633.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, September 23rd. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, October 16th. Finally, Truist Financial raised their price objective on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $587.63.

Vertex Pharmaceuticals Trading Down 2.1%

NASDAQ VRTX traded down $11.65 on Tuesday, reaching $541.50. The company’s stock had a trading volume of 531,346 shares, compared to its average volume of 1,385,165. The business has a 50-day moving average price of $523.32 and a 200 day moving average price of $479.96. The firm has a market cap of $137.44 billion, a PE ratio of 31.49, a price-to-earnings-growth ratio of 2.54 and a beta of 0.28. Vertex Pharmaceuticals has a 52 week low of $403.16 and a 52 week high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the business posted $4.80 earnings per share. The firm’s revenue was up 11.8% compared to the same quarter last year. Analysts anticipate that Vertex Pharmaceuticals will post 16.74 earnings per share for the current fiscal year.

Institutional Trading of Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of VRTX. BlackRock Inc. bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $11,975,849,000. State Street Corp lifted its stake in shares of Vertex Pharmaceuticals by 1.2% during the 2nd quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock worth $5,896,910,000 after buying an additional 141,320 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Vertex Pharmaceuticals by 1.1% during the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock worth $1,613,209,000 after buying an additional 35,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Vertex Pharmaceuticals by 1.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock worth $1,533,248,000 after buying an additional 29,287 shares during the period. Finally, Bank of America Corp DE bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth about $1,509,651,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, exceeding the $3.42 billion consensus estimate. Growth was supported by the company’s cystic fibrosis franchise and the ramp-up of newer products, including CASGEVY and JOURNAVX. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Vertex raised its full-year 2026 revenue outlook to $13.2 billion-$13.3 billion and highlighted continued pipeline advancement and the completed acquisition of Crinetics Pharmaceuticals. Analysts also became more constructive: Cantor Fitzgerald raised its price target to $619 from $595 and maintained an “overweight” rating. Cantor Fitzgerald Vertex rating
• Neutral Sentiment: Stifel Nicolaus increased its price target to $563 from $500 but retained a “hold” rating, signaling that much of the expected upside may already be reflected in the shares. Stifel Nicolaus Vertex rating
• Negative Sentiment: Adjusted earnings of $4.76 per share fell short of estimates ranging from $4.82 to $4.92 and declined from $4.80 a year earlier. Heavy investment in new product launches and the Crinetics transaction limited profit growth despite higher sales. Vertex spends cash flow on new launches
• Negative Sentiment: The revenue outlook is only modestly above the previous forecast and roughly in line with consensus, which may disappoint investors looking for a larger guidance increase. The mixed earnings report has produced a volatile reaction, with the earnings miss and light outlook offsetting the revenue beat.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.